ipilimumab + nivolumab + encorafenib + binimetinib

**Ipilimumab + nivolumab + encorafenib + binimetinib** is a quadruplet combination therapy investigated for **BRAF V600-mutant metastatic melanoma**, particularly with brain metastases. It pairs immune checkpoint inhibitors **ipilimumab** (anti-CTLA-4 monoclonal antibody) and **nivolumab** (anti-PD-1 monoclonal antibody), which unleash T-cell responses against tumors, with targeted agents **encorafenib** (BRAF inhibitor) and **binimetinib** (MEK inhibitor) that block the MAPK pathway downstream of mutant BRAF. This regimen aims to combine immunotherapy and targeted therapy upfront for synergistic antitumor effects in advanced melanoma, as explored in phase I/II trials like QUAD01 (NCT04655157).[1][6][7][8]